References
- Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591–1603.
- Mazurek JM, Syamlal G, Wood JM, et al. Malignant mesothelioma mortality- United States, 199902015. MMWR Morb Mortal Wkly Rep. 2017;66:214–218.
- O’Brien ME, Waltkins D, Ryan C, et al. A randomized trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol. 2006;2:270–275.
- Hawley R, Monk A. Malignant mesothelioma: current practice and research directions. Collegian Austrian J Nurs Pract Scholarship Res. 2004;11(2):22–26.
- Antman K, Shermin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and women’s hospital experience over two decades, 1965-1985. J Clin Oncol. 1988;6(1):147–153.
- Kazan-Allen L. Asbestoes and mesothelioma: worldwide trends. Lung Cancer. 2005;49:S3–S8.
- Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2011. Bethesda (MD): National Cancer Institute; 2014. Available from:. based on November 2013 SEER data submission, posted to the SEER web site, April 2014: https://seer.cancer.gov/archive/csr/1975_2011/
- Faig J, Howard S, Levine EA, et al. Changing pattern in malignant mesothelioma survival. Transl Oncol. 2015;8(1):35–39.
- Grunfeld E, Earle CC. The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monographs. 2010;40:25–30.